Hempyreum.org
Local Time
English (UK) Deutsch (DE) Français (FR) Español (ES) Italian (IT)
Review of CBD Studies Indicates Cannabinoid’s Antipsychotic Effects
Author: Monterey Bud 29/11/2017 - 17:15:00

Performed in the Netherlands, a review of existing research on Cannabidiol – aka, the CBD cannabinoid found in marijuana – has underscored the compound’s efficacy as an antipsychotic medication. 

In another victory for Cannabidiol, the recent review of existing research has determined the CBD cannabinoid found in cannabis is more effective at reducing antipsychotic episodes than currently prescribed pharmaceuticals with fewer side effects. 

Schizophrenia affects approximately 3.5 million people in the U.S. and typically begins in early childhood, usually afflicting those between the ages of 15 and 25. Males historically succumb to schizophrenia at a slightly earlier age than females. While symptoms of schizophrenia are first detectable in men between the age of 16 and 25, the average female afflicted with schizophrenia realize their symptoms several years later, with an elevated incidence in women over 30. 

More on marijuana.com:Review of CBD Studies Indicates Cannabinoid’s Antipsychotic Effects


©2017 - Hempyreum.org - News aggregator about Hemp and Cannabis [Beta] | All rights and ownership of the contents belong to their respective holders

Advertising